Urinary Urinary Nerve Growth Factor (NGF) as a Biomarker for Mixed Urinary Incontinence

Exclusion Criteria

• •The subject has WBC≧3, Albumin≧+1, Nit ≧+1 upon urinalysis
• •On an unstable dosage of any drug with anticholinergic side effects, or expected to start such treatment during the study
• •Patient has a significant pelvic orgen prolapse (POP) of ICS Stage 3 or over 3.
• •Patients with combined POP surgery.
• •Patients with bladder outlet obstruction on UDS or physical exam
• •Patients with detrusor underactivity
• •Diagnosed or suspected interstitial cystitis or bladder cancer
• •History of radiation therapy on pelvic cavity
• •Patients with neurologic condition which can affect lower urinary tract function
• •History of urogenical malignancy within recent 2 years
• •Treatment within the 14 days preceding enrollment, or expected to initiate treatment during the study with:
• •i)Any anticholinergic drugs and any drug treatment affecting lower urinary tract function Estrogen treatment started more than 2 months prior to inclusion is allowed. ii) electrostimulation, bladder training, electromagnetic treatment
• •Patient is on anti-coagulation therapy.
• •Any other condition which, in the opinion of the investigator, makes the patient unsuitable for inclusion